JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Corvus Pharmaceuticals Inc

Geschlossen

7.3 1.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.14

Max

7.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

-23M

-8M

Gewinnspanne

-13,764.773

Angestellte

31

EBITDA

-360K

-10M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+94.99% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

12. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

224M

557M

Vorheriger Eröffnungskurs

5.34

Vorheriger Schlusskurs

7.3

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2025, 20:49 UTC

Ergebnisse

Correction to Thermo Fisher Article on Oct. 22

23. Okt. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. Okt. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. Okt. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. Okt. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -2-

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. Okt. 2025, 22:17 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. Okt. 2025, 21:41 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. Okt. 2025, 21:05 UTC

Ergebnisse

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Okt. 2025, 20:35 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. Okt. 2025, 20:28 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. Okt. 2025, 20:15 UTC

Market Talk
Ergebnisse

Global Commodities Roundup: Market Talk

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Adj EPS $1.71

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Sales $5.52B

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q EPS $1.67

23. Okt. 2025, 20:09 UTC

Ergebnisse

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. Okt. 2025, 20:07 UTC

Ergebnisse

Blackstone Looks to IPOs for Investment Exits -- Update

23. Okt. 2025, 20:05 UTC

Ergebnisse

Intel 3Q Gross Margin 38.2% >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel: 4Q Guidance Excludes Altera >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Sees 4Q Adj EPS 8c >INTC

Peer-Vergleich

Kursveränderung

Corvus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

94.99% Vorteil

12-Monats-Prognose

Durchschnitt 14 USD  94.99%

Hoch 16 USD

Tief 11 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Corvus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.165 / 3.5827Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat